New obesity drug enters early human testing
NCT ID NCT07291232
First seen Jan 04, 2026 · Last updated May 17, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug called ABBV-295 in 48 adults with obesity. The main goals are to check safety, how the drug moves through the body, and any weight changes. Participants receive multiple injections of the drug or a placebo over several weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 278624
RECRUITINGGrayslake, Illinois, 60030, United States
Conditions
Explore the condition pages connected to this study.